## **UTILITY PATENT APPLICATION TRANSMITTAL**

Attorney Docket No. First Inventor		509582000110		
		David H. MCDANIEL		
Title	ULTRASOUN	DENHANCEMENT OF PERCUTANEOUS DRUG ABSORPTION		
	Data	lung 9, 2004		

nly for new nonprovisional applications under 37 CFR 1.53(b))

June 8, 2001

## **CERTIFICATE OF HAND DELIVERY**

Rereby certify that this	correspondence is being hand	filed with the United	States Patent and	Trademark Office in Washi	ington, D.C. on
<b>0</b> ne 8, 2001.	$\mathcal{D}_{\bullet}$	.00 H-ta	to		,

	PTC	Renell G. Feimster						
	<u>=</u> 0	APPLICA See MPEP chapter 600 con	ATION ELEMENTS	eation contents.	,	ADDRESS TO: Bo	ommissioner for Pate ox Patent Application ashington, DC 20231	1
	1	Fee Transmittal Form (Submit an original, and a duy Applicant claims smal See 37 CFR 1.27. Specification (preferred arrangement set for Descriptive title of the Inversion of th	(e.g. PTO/SB/17) plicate for fee processing) Il entity status.  [Total Pag orth below) rention red Applications d sponsored R & D sting, a table, or a appendix ion ention rawings (if filed)	es 42 ]	7.	CD-ROM or CD-R in Program (Appendix) Nucleotide and/or Ar (if applicable, all necessary.  Computer Respecification Sequence i. CD-ROM or Clii. paper Statements very ACCOMPANYI  Assignment Papers (co 37 CFR 3.73(b) Statem (where there is an assigneed)	mino Acid Sequence) eadable Form (CRF) Listing on: D-R (2 copies); or verifying identify of about NG APPLICATION over sheet & document lient e)	ble or Computer se Submission ove copies
	4. <b>X</b> 5.	b. Copy from (for continue i. DELE Signer	[Total She [Total Pag ecuted (original or copy) In a prior application (37 CI lation/divisional with Box 18 co ETION OF INVENTOR(S) Individual statement attached deleting application, see 37 CFR 1.63(c)	FR 1.63(d)) mpleted) inventor(s) named in the	11.	English Translation doc Information Disclosure : (IDS)/PTO-1449 Preliminary Amendmen Return Receipt Postcar Should be specifically itemi. Certified Copy of Priorit (if foreign priority is claimed Request and Certificatic	Statement  at (MPEP 503)  ized)  ty Document(s)	Copies of IDS Citations  2(b)(2)(B)(i). Applicant
u U	6. <b>X</b>	Application Data Sheet. See 37 CFR 1.76			must attach form PTO/SB/35 or its equivalent.  17. Other  Other			
	18. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:  Continuation Divisional Continuation-in-part (CIP) Of prior application No: 09/168,683 filed October 9, 1998 which is a CIP of Serial No. 09/087,146 issued as U.S. Patent No. 6,030,374  Prior application information: Examiner: Deborah Blyeis Group / Art Unit: 3763  For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an eath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. This incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.							
l				19. CORRESPOND	DENCE A	DDRESS		
	Customer Number or Bar Code Label			25227 PATENT TRADEMARK OFFICE  (Insert Customer No. or Attach bar code label here)		FICE	or Correspondence address below	
ļ	Name							
	Address City							
ļ	Country			Telephone	1		Fax	
ŀ	Name (Print/Type)  Signature  Alex Char			\ Cut	Registratio	n No. (Attorney/Agent) Date Jun	31,942 ne 8, 2001	

ATTORNEY DOCKET	-	DATE June 8, 2001
		PERCUTANEOUS DRUG ABSORPTION
PAPERS ENCLOSED:		I INCOMMONDE DESCRIPTION
PECIFICATION	PAGES	☐ DECLARATION
LAIMS	<b>16</b> PAGES	☐ ASSIGNMENT WITH RECORDATION
BSTRACT	1PAGES	☐ CERTIFICASE OF EXPRESS MAIL
<b>A</b> DRAWINGS	SHEETS	VERIFIED STATEMENT
☐ FILING FEE CHECK	\$	7NN 0 8 5004 (F)
0		JUN STEEL
		AXC/rgf

RECEIVED BY THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

JAN - 9 2002

1C 3700 MAIL ROOM